A Study of Adjuvant Chemoradiotherapy with Tri-weekly Cisplatin for Postoperative High-risk Oral Squamous Cell Carcinoma.
|Abstract||The aim of this study was to assess the feasibility and safety profile of concurrent chemoradiotherapy with cisplatin in Japanese patients with postoperative high-risk oral cancer.|
Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.
|Journal Title||the tokai journal of experimental and clinical medicine|
|Publication Year Start||2017-01-01|
PMID- 28413867 OWN - NLM STAT- MEDLINE DA - 20170417 DCOM- 20170428 LR - 20170428 IS - 2185-2243 (Electronic) IS - 0385-0005 (Linking) VI - 42 IP - 1 DP - 2017 Apr 20 TI - A Study of Adjuvant Chemoradiotherapy with Tri-weekly Cisplatin for Postoperative High-risk Oral Squamous Cell Carcinoma. PG - 19-24 AB - OBJECTIVE: The aim of this study was to assess the feasibility and safety profile of concurrent chemoradiotherapy with cisplatin in Japanese patients with postoperative high-risk oral cancer. METHODS: Patients with high-risk pathological features were selected from patients with oral squamous cell carcinoma who underwent surgery at the Department of Oral and Maxillofacial Surgery, Tokai University Hospital. Patients were given adjuvant chemoradiotherapy with tri-weekly cisplatin (100 mg/m2) (66 Gy/33 Fr), and the treatment completion rate was examined. RESULTS: A total of 27 patients were enrolled between April 2011 and December 2012, including 19 males and 8 females. The median follow-up period was 36 months, and the protocol completion rate was 81.5%. Grade 3 or higher adverse events included leukopenia in 16 patients (59.3%), anemia in 7 patients (25.9%), mucositis in 2 patients (7.4%), increased creatinine in 1 patient (3.7%), nausea in 4 patients (14.8%), and anorexia in 12 patients (44.4%). The 3-year overall survival rate was 66.7%, relapse-free survival rate was 63.0%, and locoregional control rate was 77.8%. CONCLUSION: The feasibility and safety profile of concurrent chemoradiotherapy with cisplatin in Japanese patients with postoperative high-risk oral cancer were comparable to pivotal phase III trials. FAU - Otsuru, Mitsunobu AU - Otsuru M AD - Department of Oral and Maxillofacial Surgery, Division of Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. [email protected] FAU - Ota, Yoshihide AU - Ota Y FAU - Aoki, Takayuki AU - Aoki T FAU - Sasaki, Masashi AU - Sasaki M FAU - Suzuki, Takatugu AU - Suzuki T FAU - Denda, Yuya AU - Denda Y FAU - Takahashi, Miho AU - Takahashi M FAU - Akiba, Takeshi AU - Akiba T FAU - Kaneko, Akihiro AU - Kaneko A LA - eng PT - Journal Article DEP - 20170420 PL - Japan TA - Tokai J Exp Clin Med JT - The Tokai journal of experimental and clinical medicine JID - 7704186 RN - 0 (Antineoplastic Agents) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Adult MH - Aged MH - Antineoplastic Agents/*administration & dosage MH - Asian Continental Ancestry Group MH - Carcinoma, Squamous Cell/surgery/*therapy MH - *Chemoradiotherapy, Adjuvant MH - Cisplatin/*administration & dosage MH - Drug Administration Schedule MH - Feasibility Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mouth Neoplasms/surgery/*therapy MH - Postoperative Period MH - Prognosis MH - Radiotherapy Dosage MH - Risk MH - Safety EDAT- 2017/04/18 06:00 MHDA- 2017/04/18 06:00 CRDT- 2017/04/18 06:00 PHST- 2016/11/08 [received] PHST- 2016/12/08 [accepted] PST - epublish SO - Tokai J Exp Clin Med. 2017 Apr 20;42(1):19-24.
<?xml version="1.0" encoding="UTF-8"?> <b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" > </b:Sources>